539 related articles for article (PubMed ID: 25880207)
41. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
JAMA Ophthalmol; 2013 Oct; 131(10):1288-95. PubMed ID: 23787820
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
43. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
[TBL] [Abstract][Full Text] [Related]
44. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.
Rácz P; Ruzsonyi MR; Nagy ZT; Gaygi Z; Bito LZ
Arch Ophthalmol; 1996 Mar; 114(3):268-73. PubMed ID: 8600885
[TBL] [Abstract][Full Text] [Related]
45. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
[No Abstract] [Full Text] [Related]
46. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
[TBL] [Abstract][Full Text] [Related]
47. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension.
Mundorf TK; Ogawa T; Naka H; Novack GD; Crockett RS;
Clin Ther; 2004 Apr; 26(4):541-51. PubMed ID: 15189751
[TBL] [Abstract][Full Text] [Related]
48. Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
Yamamoto T; Ikegami T; Ishikawa Y; Kikuchi S;
Am J Ophthalmol; 2016 Nov; 171():35-46. PubMed ID: 27565224
[TBL] [Abstract][Full Text] [Related]
49. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
[TBL] [Abstract][Full Text] [Related]
50. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
51. The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure.
Özyol E; Özyol P
J Glaucoma; 2016 Feb; 25(2):135-9. PubMed ID: 25264990
[TBL] [Abstract][Full Text] [Related]
52. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.
Konstas AG; Maltezos AC; Gandi S; Hudgins AC; Stewart WC
Am J Ophthalmol; 1999 Jul; 128(1):15-20. PubMed ID: 10482089
[TBL] [Abstract][Full Text] [Related]
53. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
[TBL] [Abstract][Full Text] [Related]
54. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
García Sanchez J
Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study.
Shedden A; Laurence J; Tipping R;
Clin Ther; 2001 Mar; 23(3):440-50. PubMed ID: 11318078
[TBL] [Abstract][Full Text] [Related]
57. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy.
Konstas AG; Mikropoulos D; Dimopoulos AT; Moumtzis G; Nelson LA; Stewart WC
Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
59. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.
Suzuki K; Otsuka N; Hizaki H; Hashimoto M; Kuwayama Y;
Adv Ther; 2018 Jun; 35(6):796-808. PubMed ID: 29873009
[TBL] [Abstract][Full Text] [Related]
60. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
Alm A; Stjernschantz J
Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
